Changes in circulating immature and mature dendritic cells during IL-2 cancer immunotherapy and their relation with lymphocyte increase and clinical response

Hematology

Volumn 5, Issue 2, 2000, Pages 117-125

  Lissoni, P ^a   Bonfanti, A ^a   Bordin, V ^a   Barni, S ^a   Vigore, L ^a   Ferrante, R ^a   Rovelli, F ^a   Fumagalli, L ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Dendritic cells; Immunotherapy; Interleukin 12; Interleukin 2

Indexed keywords

BIOLOGICAL MARKER; CD123 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 12; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE CONTROL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 0033842329     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/10245332.2000.11746494     Document Type: Article

References (21)

1. A comparison of 2 modes of administration of rIL-2: Continuous intravenous infusion alone versus subcutaneous administration plus IFN-a in patients with advanced renal cell carcinoma
2. Prognostic value of immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-a in combination with 5FU
3. Aldesleukin (recombinant Interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma
4. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy
5. The multiple ways to tumor tolerance
6. Induction of antitumor immunity using bone marrow-generated dendritic cells
7. Human dendritic cells: Natural adjuvants in antitumor immunotherapy
8. Dendritic cells: From ontogenetic orphans to myelomonocytic descendants
9. Lymphockine-activated killer cell phenomenon
10. Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma
11. Phenotypic and functional analyses of natural killer cells: Impaired NK activity partly due to the CD56+ cell dysfunction in cancer patients
12. The role of interleukin-2, interleukin-12 and dendritic cells in cancer therapy
13. Second-line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer resistant to interferon-alpha
14. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature
15. Multidimensional flow-cytometric analysis of dendritic cells in the peripheral blood of normal donors and cancer patients
16. In vivo stimulation of IL-12 secretion by subcutaneous low-doses IL-2 in metastatic cancer patients
17. Dendritic cell differentiation in a peripheral blood mononucleated cell culture treated with interleukin-2
18. The vascular endothelial growth factor family of polypeptides
19. Production of vascular endothelial growth factor by human tumor inhibits the functional maturation of dendritic cells
20. Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: Preliminary considerations
21. Serum VEGF is an independent prognostic factor in patients with metastatic renal carcinoma treated with IL-2 and/or IFN-alpha: Analysis of the Crecy trial